Merck Drug Extends Survival in Endometrial Cancer Trial, Gets US Priority Review
Merck’s drug extended survival in an endometrial cancer trial and received priority review in the United States.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.